Teva Marion Partners was formed in 1995 as an equally owned marketing partnership between Teva and Marion Merrell Dow, a predecessor company of Aventis Pharmaceuticals, to promote COPAXONER (glatiramer acetate for injection) in North America. Today's announcement is part of a larger restructuring agreement involving both North American and European collaborations between the two companies.

"Teva Marion Partners has had tremendous success marketing COPAXONER in the United States and Canada. In the United States, COPAXONER has become the second leading multiple sclerosis product. I'm confident that Teva Neuroscience will leverage the success with COPAXONER to create a fully integrated proprietary pharmaceutical company in North America," explained Eli Hurvitz, president and chief executive officer of Teva.

The successful cooperation between Teva and Aventis, which made COPAXONER the fastest-growing multiple sclerosis therapy in North America, will continue. Aventis will continue to distribute COPAXONER in North America and receive a revenue stream from the sales of COPAXONER through 2008. Aventis retains the rights in North America to distribute an oral formulation of CopaxoneR, which is currently in Phase III clinical studies.

"This agreement allows us to continue the way we work with Teva Neuroscience regarding COPAXONER in the short term and benefits both companies longer term," said Gerald P. Belle, president of Aventis Pharmaceuticals North America. "We will continue to receive revenue from the sales of COPAXONER similar to the terms of the previous agreement and the non-compete clause will be removed, enabling Aventis Pharmaceuticals to pursue independent central nervous system opportunities."

The current leadership of Teva Marion Partners will remain intact, led by Larry Downey, president and chief executive officer. The company's North American headquarters will remain in Kansas City, Mo. The operation in Canada, headquartered in Montreal, remains under the leadership of John Hassler.

Larry Downey, president and chief executive officer of Teva Neuroscience, said, "We remain committed to enhancing the management of multiple sclerosis while we look for additional product opportunities. For example, Teva has a strong commitment to its neurology product line with two products currently in Phase III clinical studies in North America and Europe. We are excited about the prospects Teva Neuroscience holds and are committed to being a leader in the field of neurology."

Patients will continue to benefit from the many services available from Teva Neuroscience, including the MSWatchR Web site and Shared SolutionsTM patient support program.

Teva Pharmaceutical Industries Ltd. is Israel's largest pharmaceutical company, with over 85 percent of its sales outside Israel, mainly in North America and Europe. The company develops, manufactures, and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients.

Aventis Pharmaceuticals conducts the U.S. business of Aventis Pharma AG. With headquarters in Parsippany, N.J., Aventis Pharmaceuticals focuses its activities on important therapeutic areas such as cardiology, oncology, anti-infectives, arthritis, allergy and respiratory, diabetes and the central nervous system.

Aventis Pharma AG is the pharmaceutical company of Aventis S.A. (NYSE:AVE). Aventis Pharma is dedicated to treating and preventing human disease through the discovery, development, manufacture and sale of innovative pharmaceutical products aimed at fulfilling unmet medical needs. The corporate headquarters of Aventis Pharma is in Frankfurt, Germany. Aventis Pharma is comprised of Aventis Pharmaceuticals; Aventis Pasteur, a world leader in vaccines, headquartered in Lyon, France; and Aventis Behring, a world leader in therapeutic proteins, headquartered in King of Prussia, Pa.

Aventis S.A., a world leader in pharmaceuticals and agriculture, is headquartered in Strasbourg, France. The company employs approximately 95,000 people in more than 120 countries. Aventis was launched in December 1999 through the merger of Hoechst AG and Rhone-Poulenc S.A.

To receive a copy of this release or any recent release, visit the Aventis Pharmaceuticals U.S. Web site at , or call 1-800-207-8049.

Statements in this news release other than historical information are forward-looking statements subject to risks and uncertainties. Actual results could differ materially depending on factors such as the availability of resources, the timing and effects of regulatory actions, the strength of competition, the outcome of litigation and the effectiveness of patent protection. Additional information regarding risks and uncertainties is set forth in the current Annual Report on Form 20-F of Aventis on file with the Securities and Exchange Commission.